



US005837738A

# United States Patent [19]

Williamson et al.

[11] Patent Number: 5,837,738

[45] Date of Patent: \*Nov. 17, 1998

## [54] METHOD OF INHIBITING NITRIC OXIDE FORMATION

3206034 9/1991 Japan .

[75] Inventors: Joseph R. Williamson; John A. Corbett; Michael L. McDaniel, all of St. Louis, Mo.; Ronald G. Tilton, Sugarland, Tex.

[73] Assignee: Washington University, St. Louis, Mo.

[\*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. Nos. 5,246,970 and 5,358,969.

[21] Appl. No.: 796,654

[22] Filed: Feb. 5, 1997

## Related U.S. Application Data

[63] Continuation of Ser. No. 328,925, Oct. 25, 1994, abandoned, which is a continuation-in-part of Ser. No. 110,915, Aug. 24, 1993, Pat. No. 5,358,969, which is a continuation-in-part of Ser. No. 843,387, Feb. 28, 1992, Pat. No. 5,246,971, and a continuation-in-part of Ser. No. 906,632, Jun. 30, 1992, Pat. No. 5,246,970, said Ser. No. 843,387, said Ser. No. 906,632, is a continuation-in-part of Ser. No. 807,912, Dec. 16, 1991, abandoned.

[51] Int. Cl.<sup>6</sup> ..... A61K 31/155

[52] U.S. Cl. ..... 514/634

[58] Field of Search ..... 514/634

## [56] References Cited

## U.S. PATENT DOCUMENTS

3,541,218	11/1970	Marshall et al.	.
4,758,583	7/1988	Cerami et al.	..... 514/399
4,870,210	9/1989	Musser.	.
5,128,360	7/1992	Cerami et al.	.
5,246,970	9/1993	Williamson et al.	..... 514/632
5,246,971	9/1993	Williamson et al.	..... 514/634
5,273,875	12/1993	Griffith	..... 435/1
5,317,040	5/1994	Goldman et al.	..... 514/634
5,358,969	10/1994	Williamson et al.	..... 514/632
5,449,688	9/1995	Wahl et al.	..... 514/546

## FOREIGN PATENT DOCUMENTS

0 222 313 A2	5/1987	European Pat. Off.	.
0 316 852 A2	5/1989	European Pat. Off.	.
0 339 496 A2	11/1989	European Pat. Off.	.

3206034 9/1991 Japan .

## OTHER PUBLICATIONS

- Henrichs (1990), *Pharm. Ztg.* 135:1711-24.  
Vissara (1990), Chronic Diabetic Complications and Tissue Glycosylation Relevant Concern for Diabetes-Prone Black Population, *Diabetes Care* 13:1180-5.  
Kieronska et al. (1978), The Influence of Aminoguanidine Derivatives on the Process of Humoral and Cellular Immunogenesis, *Achivum Immunologiae* 26:959-62.  
Bach, 1994, Endocrine Rev. 15:516-42.  
Masferrer et al., 1994, Proc. Natl. Acad. Sci. USA 91:3228-32.  
Salvemini et al., 1994, J. Clin. Invest. 93:1940-47.  
Corbett et al., 1993, Autoimmunity 15:145-53.  
Corbett et al., 1993, Biochemistry 32:13767-70.  
Corbett et al., 1992, Biochem. J. 287:229-35.  
Fletcher et al., 1992, J. Biol. Chem. 267:4338-44.  
Bucala et al., 1991, J. Clin. Invest. 87:432-38.  
Ialenti et al., 1992, European J. Pharmacol. 211:177-82.  
Kihara et al., 1991, Proc. Natl. Acad. Sci. USA 88:6107-11.

- Pugliese et al., 1991, Diabetes/Metabolism Rev. 7:35-59.  
Stuehr et al., 1991, Proc. Natl. Acad. Sci. USA 88:7773-77.  
Southern et al., 1990, FEBS. Lett. 276:42-44.  
Hibbs et al., 1990, *Nitric Oxide from L-Arginine: A Bioregulatory System*, Moncada and Higgs, Eds., Elsevier, NY, pp. 189-223.  
Williamson et al., 1990, Diabete & Metab. 16:369-70.  
Brownlee et al., 1988, New Engl. J. Med. 318:1315-21.  
Herbort et al., 1988, Graefe's Arch. Clin. Exp. Ophthalmol. 226:553-58.  
Brownlee et al., 1986, Science 232:1629-32.  
Cousins et al., 1984, Exp. Eye Res. 39:665-26.

Primary Examiner—Raymond Henley, III  
Attorney, Agent, or Firm—Howell & Haferkamp, L.C.

## [57] ABSTRACT

A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.

3 Claims, 7 Drawing Sheets